Leerink Partners on Akebia Therapeutics (AKBA): approval of TVTX's Filspari in FSGS provides positive readthrough

April 14, 2026 10:59 AM

Leerink Partners analyst Roanna Ruiz reiterated an Outperform rating and $3.00 price target on Akebia Therapeutics (NASDAQ: AKBA)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found